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A 41-year-old woman presented to hospital with anterior neck swelling and pain, made worse with swallowing, after a week of 
febrile upper respiratory illness. She had an exqui-
sitely tender goitre and fine hand tremor. Her tem-
perature was 37.1°C, with a resting heart rate of 
92–122  beats/minute and blood pressure of 
116/68 mm Hg. Her thyroid-stimulating hormone 
was undetectable at < 0.01 (normal range 0.35–5.50) 
mU/L, with elevated free thyroxine (59.0 pmol/L; 
normal range 10.0–20.0), and free triiodothyronine 
(27.4 pmol/L; normal range 3.5–6.5). Her C-reactive 
protein and erythrocyte sedimentation rate were 
also elevated (Appendix 1, available at www.cmaj.
ca/lookup/doi/10.1503/cmaj.202787/tab-related 
-content). The emergency physicians excluded sup-
purative thyroiditis and thyroid abscess by com-
puted tomography (CT), which showed thyroid enlargement 
(Figure 1). An endocrinologist diagnosed subacute thyroiditis and 
prescribed a short course of oral prednisolone, ibuprofen and pro-
pranolol; the patient’s pain and goitre size reduced within 24 hours. 
After discharge from hospital, her symptoms resolved without fur-
ther intervention, followed by a period of asymptomatic hypothyrox-
inaemia, eventually returning to euthyroidism (Appendix 1).
De Quervain subacute granulomatous thyroiditis, the common-
est cause of thyroidal pain, can result from viral infection,1,2 including 
COVID-19.3 Diagnosed clinically by history, examination and blood 
tests, it is usually self-limiting. The classic triphasic pattern starts 
with an initial thyrotoxicosis lasting 3–6 weeks when preformed 
 thyroid hormones are released due to thyroid-cellular destruction. 
An intermediate hypothyroid phase of up to 6 months follows, 
because thyroid hormone stores are depleted. Of patients with the 
condition, 85%–95% return to their baseline thyroid functioning 
within 12 months. 
Thyroid imaging and biopsy are not usually required, but given 
the patient’s substantially raised inflammatory markers and intense 
pain, the emergency physicians were concerned about the possibil-
ity of suppurative thyroiditis or abscess and therefore ordered a CT 
scan. Other causes of painful thyroid conditions such as intrathyroi-
dal hemorrhage, cysts, nodules or, rarely, infiltrative cancers were 
also excluded. Ultrasonography is usually preferred for imaging of 
the thyroid as it has superior spatial resolution; in painful subacute 
thyroiditis, the gland is hypoechoic and has low-to-normal vascular-
ity on colour-flow Doppler ultrasonography.1 Symptomatic treat-
ment in the acute phase is with β-blockers for thyrotoxic symptoms 
(antithyroid medications are ineffective) and nonsteroidal anti-
inflammatory drugs for pain and inflammation. Corticosteroids are 
recommended for refractory or severe pain and thyrotoxic symp-
toms.2 Levothyroxine may be required in the hypothyroid phase but 
should be withdrawn after 3–6 months, and long-term treatment 
continued only if hypothyroidism persists.
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Figure 1: Computed tomography scan of the neck of a 41-year-old woman, performed to 
exclude acute suppurative thyroiditis or abscess, showing diffusely swollen thyroid gland 
(arrows) with heterogeneous attenuation characteristic of thyroiditis in transverse (A) and 
 sagittal (B) cross-sections. 
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